IFPE (Invisalign First Palatal Expander)
Launched by UNIVERSITY OF BRITISH COLUMBIA · Jan 19, 2024
Trial Information
Current as of March 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Purpose:
This prospective study is aimed to investigate the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions and to compare them with those of traditional maxillary expansion.
Hypothesis:
The null hypothesis will be:
* 1: There are no differences in the inter-canine, inter-molar width, and molar inclination between IFPE and RME groups.
* 2: There are no differences in the arch width, length, size and shape, palatal surface area and volume, plaque index, and white spot lesion formation between IFPE and RME groups.
* 3: There are no diffe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients in mixed dentition with 6 present on both Right and Left in the upper arch
- • Patients with transverse maxillary deficiency (presence of unilateral or bilateral crossbite, or intermolar width (as measured where the palatal groove meets the gingival margin of the first molar) of 33 mm or less)
- Exclusion Criteria:
- • multiple and/or advanced caries,
- • missing teeth due to aplasia, trauma, or deep caries,
- • supernumerary teeth,
- • congenital craniofacial malformations or congenital or acquired systematic disease,
- • previous orthodontic treatment
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0